Bangkok Genomics Innovation PCL (BKK:BKGI)
Thailand · Delayed Price · Currency is THB 2.020
+0.030 (1.51%)
Jul 24, 2026, 4:35 PM ICT
BKK:BKGI Financials Overview
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Revenue Revenue Growth | 453.15 | 379.51 | 337.59 | 245.39 | 304.77 |
Revenue Growth | 30.29% | 12.42% | 37.57% | -19.48% | - |
Gross Profit Gross Profit Growth | 186.84 | 155.63 | 140.08 | 116.1 | 157.52 |
Operating Income Operating Income Growth | 76.79 | 49.62 | 52.46 | 33.58 | 79.73 |
Net Income Net Income Growth | 68.46 | 45.35 | 50.17 | 32.14 | 75.11 |
Earnings Per Share EPS Growth | 0.11 | 0.08 | 0.09 | 0.07 | 0.35 |
EPS Growth | 40.81% | -14.55% | 21.09% | -79.20% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Testing and Analysis Services Testing and Analysis Services Growth | 276.25 | 267.25 | 256.5 | 241.38 | 290.83 |
Sale of Laboratory Reagents and Related Products Sale of Laboratory Reagents and Related Products Growth | 144.08 | 102.71 | 81.09 | 4.01 | 13.95 |
Sale Advanced Therapy Medicinal Product Sale Advanced Therapy Medicinal Product Growth | - | 12.82 | - | - | - |
Elimination Elimination Growth | - | -3.27 | - | - | - |
Total Total Growth | 453.15 | 379.51 | 337.59 | 245.39 | 304.78 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Investments Cash & Investments Growth | 136.99 | 221.74 | 389.93 | 165.9 | 148.36 |
Total Debt Total Debt Growth | 20.28 | 21.47 | 24 | 23.72 | 31.63 |
Net Cash (Debt) Net Cash Growth | 116.71 | 200.27 | 365.93 | 142.18 | 116.73 |
Net Cash Growth | -67.38% | -45.27% | 157.36% | 21.80% | - |
Net Cash Per Share Net Cash Per Share Growth | 0.19 | 0.33 | 0.65 | 0.32 | 0.55 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -52.27 | -92.32 | -3.5 | 71.85 | 80.74 |
Capital Expenditures CapEx Growth | -16.02 | -15.1 | -19.96 | -4.82 | -26.84 |
Free Cash Flow Free Cash Flow Growth | -68.29 | -107.41 | -23.46 | 67.03 | 53.9 |
Free Cash Flow Growth | - | - | - | 24.36% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Gross Margin | 41.23% | 41.01% | 41.49% | 47.31% | 51.68% |
Operating Margin | 16.95% | 13.07% | 15.54% | 13.69% | 26.16% |
Pretax Margin | 16.58% | 12.61% | 15.11% | 13.02% | 25.81% |
Profit Margin | 15.11% | 11.95% | 14.86% | 13.10% | 24.64% |
FCF Margin | -15.07% | -28.30% | -6.95% | 27.31% | 17.68% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.050 | 0.050 | 0.050 | 0.054 | 4.666 |
Dividend Per Share Growth | 0% | 0% | -8.26% | -98.83% | - |
Dividend Yield | 2.51% | 4.15% | 2.42% | - | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
PE Ratio | 17.70 | 16.54 | 26.31 | - | - |
Forward PE | - | 26.32 | 20.95 | - | - |
PS Ratio | 2.67 | 1.98 | 3.91 | - | - |